Replies to post #116041 on Biotech Values

[DewDiligence]

I take it that presuming VRTX and MRK get their [HCV] compounds approved, future trials will have to compare to one of the PI's+PEG/Riba?

In the genotype-1 first-line setting, the answer is almost certainly yes. In the genotype-1 second-line setting, the answer is maybe. For non-genotype-1 patients, the answer is no.

[DewDiligence]

ghmm et al: The EASL abstract you posted is for GS-5885, the NS5A inhibitor from GILD (not ABT). Regards, Dew